Cargando…

Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease

Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD)....

Descripción completa

Detalles Bibliográficos
Autores principales: Naruse, Hiroyuki, Ito, Hiroyasu, Izawa, Hideo, Sarai, Masayoshi, Ishii, Junnichi, Sakaguchi, Eirin, Murakami, Reiko, Ando, Tatsuya, Fujigaki, Hidetsugu, Saito, Kuniaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658500/
https://www.ncbi.nlm.nih.gov/pubmed/34884205
http://dx.doi.org/10.3390/jcm10235498
_version_ 1784612747354308608
author Naruse, Hiroyuki
Ito, Hiroyasu
Izawa, Hideo
Sarai, Masayoshi
Ishii, Junnichi
Sakaguchi, Eirin
Murakami, Reiko
Ando, Tatsuya
Fujigaki, Hidetsugu
Saito, Kuniaki
author_facet Naruse, Hiroyuki
Ito, Hiroyasu
Izawa, Hideo
Sarai, Masayoshi
Ishii, Junnichi
Sakaguchi, Eirin
Murakami, Reiko
Ando, Tatsuya
Fujigaki, Hidetsugu
Saito, Kuniaki
author_sort Naruse, Hiroyuki
collection PubMed
description Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD-IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD-IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD-IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection.
format Online
Article
Text
id pubmed-8658500
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86585002021-12-10 Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease Naruse, Hiroyuki Ito, Hiroyasu Izawa, Hideo Sarai, Masayoshi Ishii, Junnichi Sakaguchi, Eirin Murakami, Reiko Ando, Tatsuya Fujigaki, Hidetsugu Saito, Kuniaki J Clin Med Article Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD-IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD-IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD-IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection. MDPI 2021-11-24 /pmc/articles/PMC8658500/ /pubmed/34884205 http://dx.doi.org/10.3390/jcm10235498 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Naruse, Hiroyuki
Ito, Hiroyasu
Izawa, Hideo
Sarai, Masayoshi
Ishii, Junnichi
Sakaguchi, Eirin
Murakami, Reiko
Ando, Tatsuya
Fujigaki, Hidetsugu
Saito, Kuniaki
Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
title Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
title_full Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
title_fullStr Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
title_full_unstemmed Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
title_short Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
title_sort immunogenicity of bnt162b2 mrna covid-19 vaccine in patients with cardiovascular disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658500/
https://www.ncbi.nlm.nih.gov/pubmed/34884205
http://dx.doi.org/10.3390/jcm10235498
work_keys_str_mv AT narusehiroyuki immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT itohiroyasu immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT izawahideo immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT saraimasayoshi immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT ishiijunnichi immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT sakaguchieirin immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT murakamireiko immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT andotatsuya immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT fujigakihidetsugu immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease
AT saitokuniaki immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease